Skip to main content

Tweets

Simulation modeling by Patel et al helps generate probability of remission, relapse, and adverse events in newly dx AAV Projected risk by model were similar to observed rates in RCTs @RheumNow #ACR25 Abst 1764 https://t.co/xevkJ2Ih0M
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
6 months 4 weeks ago
Rotation or Change in Biologic post TNFi failure in axSpA. Switching biologic class after TNFi failure improved outcomes in axial SpA. In a randomized trial of axSpA patients with inadequate response to a first TNFi, switching to an IL-17Ai was not superior to cycling to a second https://t.co/MEsokWeT8e
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
6 months 4 weeks ago
This cohort study from Ontario of 🚺w/axSpA ✳️GDM, antepartum hem, SMM (severe maternal morbidity) -⬆️ in axSpA ✳️Neonat complications-preterm birth Factors assoc w/SMM- age, comorbidity, gestational age at delivery Better strategies for maternal care #ACR25 @RheumNow Abs2200 https://t.co/LrVzJLnvWe
6 months 4 weeks ago
HCQ weight-based dosing: out HCQ whole blood monitoring: in Whole blood levels more precisely balance risks of SLE flare (under-dosing) vs. toxicitiy (over-dosing) Many pt on <5 mg/kg had supra-therapeutic blood levels with risk for toxicity @RheumNow #ACR25 #ACRBest Abst 1722 https://t.co/qIbACxAW39
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
6 months 4 weeks ago
Mimics of ANCA-associated vasculitis: How can we tell? With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic https://t.co/LYRk0rHlzx
Dr. John Cush @RheumNow ( View Tweet )
6 months 4 weeks ago
#1727 360k+ postmenopausal women w osteoporosis: >1/3 untreated patients were at v high fracture risk, yet few received recommended anabolic or antiresorptive therapy. Even among treated women at very high risk, >50% were still on oral bisphosphonates @RheumNow #ACR25 https://t.co/9S66tAU68P
Mrinalini Dey @DrMiniDey ( View Tweet )
6 months 4 weeks ago
“I never thought I’d live to old age with MCTD, now I plan for it.” This patient’s journey highlights the power of evolving therapies, resilience, and lifestyle adaptation to age well with chronic autoimmune disease. Patient perspectives abstract #PP04 @rheumnow #ACR25

Jiha Lee @JihaRheum ( View Tweet )

6 months 4 weeks ago
#ClinicalPearl Pts w #SpA ex #PsA May have 👇 #sicca #dry #eyes #dry mouth Inflamed gallbladder without calculi 👇 Can be associated w #autoimmune disease #POTS can be initial presentation of #SjD IgA vasculitis—May have #cancer #Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
Janet Pope @Janetbirdope ( View Tweet )
6 months 4 weeks ago
Excited (and a little nervous!) to be presenting on a topic I’m very passionate about- social determinants of health & shared decision making, alongside some fantastic speakers & chairs. Join us in room W184D, 10:00-11:30 Looking forward to a lively discussion! #ACR25 @RheumNow https://t.co/FsDDrjisR3
Mrinalini Dey @DrMiniDey ( View Tweet )
6 months 4 weeks ago
Passive transfer of Ab can occur w #IVIg #Ab can occur from IVIg passive transfer incl HepB IVIg - if pt has #cryoglobulins 👇 Can precipitate severe #cryo flare #ClinicalPearl Secrets & Pearls session #ACR25 @RheumNow @ACRheum https://t.co/tTaSuVy1yQ
Janet Pope @Janetbirdope ( View Tweet )
6 months 4 weeks ago
#1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediated irAE arthritis shows hyperactive, cytotoxic CD8+ T cells & metabolic reprogramming, unlike RA. IL-6, IL-12 & IFNα fuel this process. @RheumNow #ACR25

Mrinalini Dey @DrMiniDey ( View Tweet )

6 months 4 weeks ago
#ClinicalPearl #seroneg #arthritis often has 👇 #involvement of 1st toe IP joint Look at the feet 🦶 @RheumNow @ACRheum #ACR25 #28T08 Session secrets &pearls Tues https://t.co/EfqkLsTKmt
Janet Pope @Janetbirdope ( View Tweet )
6 months 4 weeks ago
×